Study links T cell responses to COVID-19 risk in COVAIL trial participants
Analysis of the COVAIL trial shows distinct T cell correlates associated with symptomatic SARS-CoV-2 infection risk before and after a second booster dose.
This story has stopped developing; this page is its permanent record. More from that day
The story so far
1 publisher has covered this in 1 article since 6 Oct 2026. Nature Communications published first, on 6 October at 00:00 UTC.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- COVAIL